Dr. Katherine High trained in internal medicine, hematology, and molecular genetics. Her pioneering bench-to-bedside studies of gene therapy for hemophilia led to a series of basic and clinical investigations that characterized the human immune response to AAV gene delivery vectors. A long-time member of the faculty of the Perelman School of Medicine of the University of Pennsylvania, she was also an Investigator of the Howard Hughes Medical Institute at the Children’s Hospital of Philadelphia. In 2013 she co-founded Spark Therapeutics, which she joined full-time as President and Chief Scientific Officer in 2014. At Spark she led the team that achieved the first FDA approval of a gene therapy for genetic disease, Luxturna, for a congenital form of blindness, and also led the successful Phase 1/2 studies for Beqvez, now an approved gene therapy for hemophilia B. Spark Therapeutics was acquired by Roche in 2019. Dr. High is an elected member of the National Academy of Medicine, the Royal College of Physicians (London), and the National Academy of Sciences. Currently she is a Visiting Professor at Rockefeller University, and an Advisor to GV (formerly Google Ventures).